Navigation Links
Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
Date:1/28/2009

Kensey Nash Corporation Non-GAAP Financial Measures and Reconciliations Adjusted Earnings Per Share Six Months Six Months Ended Ended Year over Year December 31, December 31, % Change 2008 2007 ------------ ------------ Earnings Per Share - GAAP $0.87 $0.19 Special Charges (a) - 0.17 ---- --- Adjusted Diluted Earnings Per Share $0.87 $0.36 142% ===== ===== === (a) Diluted earnings per share for the six months ended December 31, 2007 included approximately $3.0 million in charges ($2.0 million in after-tax charges, or $0.16 per share tax-effected), for the acceleration of stock awards, and approximately $324,000 in charges ($215,000 in after-tax charges, or $0.02 per share tax-effected), related to the discontinuation of the Company's embolic protection platform, both of which were incurred during the first quarter of fiscal 2008.

    Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)
                      and Adjusted EBITDA Reconciliations

                          Six Months   Six Months
                            Ended        Ended         Year over Year
                         December 31, December 31,       % Change
                            2008          2007
                       ------------   ------------
    ($ millions)
    Net Income - GAAP      $10.5         $2.4
    Income Tax Expense       4.8          1.1
    Interest Income         (0.8)        (0.8)
    Interest Expense         1.0          0.4
    Depreciation and
     Amort
'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
3. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
4. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
7. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
8. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
9. GEN Reports on Growing Reliance on Microfluidics Technology
10. Novozymes Reports Strong 2008 Results
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... stock of United Kingdom -based Lab ... culture media and diagnostic systems. Lab ... a leading provider of microbial testing and diagnostic products ... markets. The company currently sells into more than 70 ...
(Date:8/27/2015)... GUELPH, ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. ... the three and six-month periods ended June 30, 2015. Biorem,s complete ... ( www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per ... , 2014 , 2015 , ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... needs and expertly narrows down the product choices to a manageable shortlist of ... down the list to models that fit best with the customer’s industry and ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... -Now for Exclusion of Venous Thromboembolism-, LEXINGTON, ... that the US Food and Drug Administration (FDA) ... for the HemosIL D-Dimer,assay to exclude venous thromboembolism ... and pulmonary embolism (PE), when used in,conjunction with ...
... Performance - Net Profit Up 16.8% at Constant Exchange Rates - Essilor Launches a Share Buyback Program ... the six months,ended June 30, 2008., EUR millions First-half 2008 ... ... at constant ...
... UK,s National Physical Laboratory (NPL) to survey nanotechnology capabilities ... to identify the next generation of nano and smart ... , "Advances in nanotechnology are crucial to Europe,s space ... nanomaterials group at NPL, who will be the principal ...
Cached Biology Technology:Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay 2Essilor's First-Half 2008 Results 2Essilor's First-Half 2008 Results 3Essilor's First-Half 2008 Results 4Essilor's First-Half 2008 Results 5Essilor's First-Half 2008 Results 6Essilor's First-Half 2008 Results 7Essilor's First-Half 2008 Results 8
(Date:8/17/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 2015. The new marketing campaign is being spearheaded by ... Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... retail driven marketing and brand awareness and has a ...
(Date:8/11/2015)... 11, 2015 Today, ZUK announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... latest American Chemical Society (ACS) Weekly PressPac from the ... 34 peer-reviewed journals and Chemical & Engineering News.,Please credit ... the source for this information. PressPac Archive: ... 1 FOR IMMEDIATE RELEASE, Solving the mystery of what ...
... (April 12, 2009) In certain respects, cells are ... have lots of components, but they also have lots ... are studied in aggregate (conservatives, liberals, atheists, evangelicals), they ... looked at one person at a time, individuals often ...
... a result of exposure to ionizing radiation, they must make ... for death, a process called apoptosis. It,s a ... involving what might be described metaphorically as a network of ... the cell nucleus. In intricate ways, cells orchestrate a ...
Cached Biology News:American Chemical Society Weekly PressPac -- April 8, 2009 2American Chemical Society Weekly PressPac -- April 8, 2009 3American Chemical Society Weekly PressPac -- April 8, 2009 4American Chemical Society Weekly PressPac -- April 8, 2009 5American Chemical Society Weekly PressPac -- April 8, 2009 6American Chemical Society Weekly PressPac -- April 8, 2009 7American Chemical Society Weekly PressPac -- April 8, 2009 8American Chemical Society Weekly PressPac -- April 8, 2009 9American Chemical Society Weekly PressPac -- April 8, 2009 10American Chemical Society Weekly PressPac -- April 8, 2009 11For cancer cells, genetics alone is poor indicator for drug response 2For cancer cells, genetics alone is poor indicator for drug response 3CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 2CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 3CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 4